UPDATE: H.C. Wainwright Starts Viracta Therapeutics (VIRX) at Buy, $35 PT
Tweet Send to a Friend
(Updated - May 3, 2021 7:25 AM EDT)
H.C. Wainwright analyst Robert Burns initiates coverage on Viracta Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
H.C. Wainwright analyst Robert Burns initiates coverage on Viracta Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
